<h4>Objective</h4>The optimal timing for combining brain radiotherapy with first-line third-generation EGFR tyrosine kinase inhibitors (TKIs) in patients with EGFR-mutant non-small cell lung cancer (NSCLC) and synchronous brain metastases (BM) remains uncertain. Here, EGFR is linked to non-small cell lung carcinoma.